Insights

The CSL share price has tumbled 8% this year. Here’s why these top brokers still have faith

CSL says plasma collections are recovering and the finalisation of its Vifor Pharma acquisition is imminent.
The post The CSL share price has tumbled 8% this year. Here’s why these top brokers still have faith appeared first on The Motley Fool Australia. –

Leading brokers are keeping their faith in stalwart blue-chip ASX share, CSL Limited (ASX: CSL). This is despite the biotherapies company’s shares trading 20% down on their pre-pandemic peak of $336.40.

CSL finished the session on Friday at $268.16, down 2.93% for the day and almost 8% down year-to-date.

A major reason for the CSL share price being this low is two very tough years during the pandemic. CSL relies on blood plasma donations to develop its suite of medicines and vaccines. COVID-19 lockdowns around the world, particularly in the United States, made this incredibly difficult.

What has been happening lately for CSL?

As my Fool colleague Monica reported on Tuesday, plasma collections are now roughly back to pre-pandemic levels. CSL is also using new technology to reduce the time it takes to donate plasma by 30%.

In addition, CSL is awaiting the finalisation of its acquisition of Swiss company, Vifor Pharma. Vifor is a world leader in the development and manufacture of products to treat kidney disease and iron deficiency. CSL recently told the ASX that everything was on track for the purchase to be completed next month.

The company also presented at the 2022 Macquarie Australia Conference in Sydney this week.

So, what are the experts saying about CSL?

Citi recently reaffirmed its buy rating on CSL with a share price target of $335 price target. This implies a potential 25% upside on Friday’s closing price.

Bell Potter likes CSL’s leadership position in plasma therapies and also what the Vifor Pharma buy will do for the company. The broker explained:

The soon to be completed acquisition of Vifor Pharma will add global leadership in pharmaceutical products for renal disease and iron deficiency.

The global growth in plasma volumes is expected to be around a solid 8% per annum for the foreseeable future and, in addition, the group is planning to launch new products from its very extensive Research and Development portfolio.

History of the CSL share price

The CSL share price began a fantastic decade of growth in late 2011 when it was trading at about $30. Over about the next five years, CSL shares grew in value by 225%. They cracked the $200 mark in mid-2018 and the $300 mark in early 2020.

CSL currently trades on a price-to-earnings (P/E) ratio of 52.79 and pays an annual dividend yield of 1.12%.

The post The CSL share price has tumbled 8% this year. Here’s why these top brokers still have faith appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

2 strong blue chip ASX 200 shares to buy after the market selloff according to analysts
Broker names 3 ‘champion’ ASX 200 shares to buy and hold
CSL share price lifts as plasma collections continue recovery
Here’s why the CSL share price beat the market in April
2 highly rated blue chip ASX 200 shares brokers rate as buys

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!